Radiation Dermatitis Treatment Market to Reach $700M by 2031

The global radiation dermatitis treatment market is expected to reach US$ 700 million by the end of the 2021-2031 assessment period, growing at a 5% CAGR. In the short term, by the end of 2021, sales of radiation dermatitis products are expected to total $429.7 million. Topical hydrophilic creams are expected to be in high demand, accounting for around 33% of global market value.

Radiation dermatitis, a common side effect of radiotherapy, is defined as skin irritation and damage caused by radiation exposure. This condition affects many cancer patients undergoing treatment and can range from minor redness and peeling to severe ulceration. As the global incidence of cancer increases, so does the demand for effective radiation dermatitis treatments, propelling the Radiation Dermatitis Treatment Market forward.

Get a FREE Sample Copy of Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=5945

How is Rising Cancer Prevalence Driving Demand for Radiation Dermatitis Treatment?

The International Agency for Cancer Research (IARC) reports that new cancer cases reached 19.3 million, with 10 million deaths in a single year. By 2040, these numbers are expected to exceed 29 million new cases and over 16 million deaths. As a result, many patients are turning to radiation therapy, a highly effective method for treating some of the most aggressive cancers.

Radiation therapy contributes to 40% of global cancer cures but significantly increases the risk of radiation burns, leading to various skin conditions. Consequently, the demand for radiation dermatitis dressings and treatment solutions is rising across key markets.

How Are Alternative Radiation Therapies Boosting Growth Opportunities?

Advanced radiotherapy methods, such as intensity-modulated radiation therapy (IMRT) and proton therapy, reduce the risk of radiation dermatitis by precisely targeting tumors while sparing healthy tissues from repeated exposure.

The increased adoption of these techniques, particularly in developed regions, leads to fewer cases of severe radiation dermatitis. As a result, the demand for chronic radiation dermatitis treatment products may face some limitations.

Country-Wise Analysis 

According to the Skin Cancer Foundation, over 9,500 persons in the United States are diagnosed with skin cancer each day, with more than one-third of them dying every hour. In 2012, more than 3.3 million people had treatment for non-melanoma skin cancer. In addition, by the age of 70, at least one in every five Americans will have developed skin cancer.

As a result, the risk of radiation dermatitis has increased in recent years. According to the American Society for Radiation Oncology (ASTRO), over 95% of patients getting radiation therapy experience some degree of radiation dermatitis, necessitating treatment, which expands market opportunities.

In recent years, there has been an increase in the number of manufacturers of topical steroid creams and oral medications for radiation dermatitis in the United States. For example, AdvaCare Pharma sells the CortiCareTM Hydrocortisone Ointment, which helps to relieve inflammation, redness, and swelling. Similarly, the 3MTM CavilonTM No Sting Barrier Film has a sting-free composition that forms a transparent barrier over the skin, protecting it from friction and promoting moisture management. According to these developments, the market in the United States will likely grow at a CAGR of 5.3% until 2031.

Category-wise Insights

Demand for topical hydrophilic creams is expected to increase significantly because to their simplicity of application, cost-effectiveness, and increased bioavailability. These lotions provide hydration to help prevent dry, rough, itchy, and scaly skin. Hydrophilic creams are expected to have a long-term market share of 33%.

Radiation treatment frequently destroys moisture content from the skin, leaving it exceedingly dry and itchy, necessitating copious amounts of water to alleviate the persistent irritation. 3M Company, for example, offers CavilonTM Advanced Skin Protectant, which is made up of a hydrophilic elastomeric polymer and a non-stinging solvent.

Fact, by distribution channel.Given the rise in home-based and self-treating prescriptions in major countries, MR anticipates that sales of radiation dermatitis treatment products will rapidly increase throughout retail pharmacies. Additionally, patients have easy access to retail pharmacies.

At the same time, online pharmacies are becoming more well-known since more patients are looking for virtual alternatives as digital literacy rises and makes smart devices and the internet more accessible. Customers choose these channels because they provide home delivery alternatives and steep savings. Together, the two channels will probably provide 45% of total income.